Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,016 recruiting studies in this area right now.
By phase
- Not applicable2,803
- Phase 2754
- Phase 1521
- Phase 3382
- Phase 1/Phase 2292
- Phase 4205
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,190
- Melanoma175
- Metastatic Breast Cancer137
- Rheumatoid Arthritis132
- Atopic Dermatitis127
- Systemic Lupus Erythematosus120
- Breast Neoplasms111
- Triple Negative Breast Cancer111
- Colorectal Cancer94
- Ovarian Cancer92
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)67
- Diabetic Foot Ulcer59
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Memorial Sloan Kettering Cancer Center48
- Novartis Pharmaceuticals48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University35
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona153
- Alabama130
- Florida125
- New York111
- Texas105
- Maryland94
- Massachusetts88
- Pennsylvania72
- North Carolina67
Recruiting studies5,016 total
- NCT07462741Recruiting
Education program for diabetic hemodialysis patients
This study tests if a special education program helps people with diabetes who are on hemodialysis (a type of kidney treatment). The goal is to see if learning more about managing their health can improve their overall well-being.
Elâzığ, MerkezAges 18 years+ - NCT07760012Recruiting
Pet scan with new tracer for solid tumors
This study uses a new imaging tracer, called 68Ga-SorB, during a PET/CT scan to look at tumors. It may help doctors see cancer more clearly. The trial is for adults with certain types of solid tumors (such as melanoma, liver, lung, breast, pancreatic, ovarian, or bile duct cancer) who need a PET/CT scan as part of their care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06623396RecruitingPhase 1
Mesothelin-targeted CAR T cells for esophagogastric cancer or mesothelioma
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
Basking Ridge, New JerseyAges 18 years+ - NCT07085442Recruiting
Targeted biopsy for breast cancer that has spread to lymph nodes
This study reviews patients with early breast cancer that has spread to a small number of lymph nodes. It looks at how well a special biopsy removes those nodes during surgery, to help guide future care.
BurnleyAges 18 years+ - NCT07726342RecruitingPhase 2
Study of a new drug for advanced HER2-positive breast cancer
This study tests a new drug, SMP-656, for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if it can help shrink or control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07876349Recruiting
Genetic testing program for breast and ovarian cancer risk
This study tests a program that helps primary care doctors identify women who may benefit from genetic testing for hereditary breast and ovarian cancer. The program uses family history to guide testing and aims to make it easier for patients to get tested.
New York, New YorkAges 21–75 - NCT07203729RecruitingPhase 2
A new drug for advanced breast cancer with severe symptoms
This trial tests a new drug called SHR-A1811 (a type of targeted therapy) for people with advanced breast cancer that is HER2-low and is causing severe symptoms (visceral crisis). The drug is given alone and aims to control the cancer and relieve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07436663RecruitingPhase 4
Preventing heart damage from breast cancer chemotherapy with two diabetes drugs
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Tanta, ElgharbeyaAges Any age - NCT06948110Recruiting
Searching for genes linked to autoimmune diseases
This study looks for genes that may be linked to autoimmune diseases by comparing the DNA of people with these conditions to healthy family members or volunteers. If you have an autoimmune disease or are a healthy person interested in helping research, this study may help scientists understand why these diseases run in families.
Bethesda, MarylandAges 18–115 - NCT07678372Recruiting
Ozoaqua for abdominal scar healing after surgery
This trial tests whether Ozoaqua, a special treatment, helps heal abdominal scars better than standard care after open surgery. It may reduce scarring and improve how the scar looks and feels.
Pamplona, NavarreAges 18 years+ - NCT07111065RecruitingPhase 2
Fatty Acid Supplement for Dermatomyositis
This study tests whether taking a fatty acid supplement (omega-3) for 6 months can help reduce disease activity in people with dermatomyositis. Participants will also receive dietary coaching and have regular check-ups at the NIH to monitor their progress.
Bethesda, MarylandAges 18–60 - NCT07262983RecruitingPhase 1
Baricitinib for Job syndrome with lupus or eczema
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
Bethesda, MarylandAges 12–120 - NCT07681271RecruitingPhase 2
Testing Remibrutinib for papulopustular rosacea
This study tests an experimental drug called remibrutinib (taken as a pill) to see if it can safely reduce the redness and bumps caused by papulopustular rosacea. It is for people with moderate to severe symptoms who have not had success with other treatments.
El Paso, TexasAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Beverly Hills, CaliforniaAges 18 years+ - NCT07482787RecruitingPhase 3
Study of SD-101 for epidermolysis bullosa in children
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
Rancho Santa Margarita, CaliforniaAges 4 weeks–12 years - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT07386743RecruitingPhase 3
New injection for moderate-to-severe eczema
This study tests a new injection called GS101 compared to an existing treatment (Dupixent) for people with moderate-to-severe atopic dermatitis (eczema). If you join, you may receive either the new drug or the standard treatment, and researchers will track how well it controls your symptoms.
Shenyang, LiaoningAges 18–75 - NCT07754786RecruitingPhase 3
Comparing a new eczema medicine with dupilumab
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
Guangzhou, GuangdongAges 18–75 - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT07765888RecruitingPhase 3
Tilrekimig for moderate-to-severe eczema
This study tests an investigational medicine called Tilrekimig for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with standard treatments. It aims to see if the medicine can reduce symptoms and improve quality of life.
Birmingham, AlabamaAges 12 years+ - NCT07029828RecruitingPhase 3
Long-term study of ritlecitinib for severe alopecia areata in children
This study tests a medicine called ritlecitinib for children with severe alopecia areata (a condition causing hair loss). It is for kids who have already completed a previous study of this medicine to see how well it works and how safe it is over a longer period.
Irvine, CaliforniaAges 6–14 - NCT07328516Enrolling by invitation
Farm childhood health study for adult children
This study looks at how early-life exposures on farms might influence long-term health. If you are an adult child of a farmer or farmworker from the Agricultural Health Study, and you spent time on a farm as a child, you may be able to join.
Bethesda, MarylandAges 18–99 - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,016 recruiting dermatology studies from the U.S. registry right now, out of 7,681 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.